Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
What Doximity (NYSE: DOCS) CFO resignation means for governance, capital allocation, and investor confidence
Read More Pharma Industry News BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens BrainStorm Cell Therapeutics narrows Q3 loss and prepares for pivotal ALS trial. Find out why 2026 could be a make-or-break year for the biotech company. bySrinathNovember 15, 2025